Retraction: Epstein-barr virus nuclear antigen 3c stabilizes gemin3 to block p53-mediated apoptosis (PLoS Pathogens (2011) 7:12 (e1002418) DOI: 10.1371/journal.ppat.1002418);Epstein-barr virus nuclear antigen 3C stabilizes gemin3 to block p53-mediated apoptosis

PLoS Pathogens

Volumn 7, Issue 12, 2011, Pages

  Cai, Qiliang ^a   Guo, Yi ^a,b   Xiao, Bingyi ^a   Banerjee, Shuvomoy ^a   Saha, Abhik ^a   Lu, Jie ^a   Glisovic, Tina ^c   Robertson, Erle S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHINA MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEAD BOX PROTEIN 20; DNA BINDING PROTEIN; EPSTEIN BARR VIRUS ANTIGEN; EPSTEIN BARR VIRUS NUCLEAR ANTIGEN 3C; PROTEIN BAX; PROTEIN P21; PROTEIN P53; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; EBNA 3C, EPSTEIN BARR VIRUS; EBNA-3C, EPSTEIN-BARR VIRUS; TP53 PROTEIN, HUMAN; VIRUS ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; ATTENUATION; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CELL PROLIFERATION; COMPLEX FORMATION; CONTROLLED STUDY; DNA BINDING; EPSTEIN BARR VIRUS; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL LINE; LYMPHOMA CELL; MEDIATOR; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; B LYMPHOCYTE; EPSTEIN BARR VIRUS INFECTION; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC TRANSFECTION; GENETICS; IMMUNOPRECIPITATION; METABOLISM; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; VIROLOGY; WESTERN BLOTTING;

HUMAN HERPESVIRUS 4;

ANTIGENS, VIRAL; APOPTOSIS; B-LYMPHOCYTES; BLOTTING, WESTERN; CELL LINE, TUMOR; DEAD BOX PROTEIN 20; EPSTEIN-BARR VIRUS INFECTIONS; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOPRECIPITATION; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84855265398     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1009556     Document Type: Erratum

References (56)

1. Burkitt D, (1958) A sarcoma involving the jaws in African children. Br J Surg 46: 218-223.
2. Epstein MA, Achong BG, Barr YM, (1964) Virus Particles In Cultured Lymphoblasts From Burkitt's Lymphoma. Lancet 1: 702-703.
3. Rickinson AB, Kieff E, (2002) Epstein-Barr virus. In: Fields BN, Knipe DM, Howley PM, editors. Fields virology, 4th ed Vol 2, Philadelphia Lippincott Williams & Wilkins pp. 2575-2627.
4. Henle G, Henle W, Diehl V, (1968) Relation of Burkitt's tumor-associated herpes-ytpe virus to infectious mononucleosis. Proc Natl Acad Sci USA 59: 94-101.
5. zur Hausen H, Schulte-Holthausen H, Klein G, Henle W, Henle G, et al. (1970) EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature 228: 1056-1058.
6. Johansson B, Klein G, Henle W, Henle G, (1970) Epstein-Barr virus (EBV)-associated antibody patterns in malignant lymphoma and leukemia. I. Hodgkin's disease. Int J Cancer 6: 450-462.
7. Kuppers R, (2003) B cells under influence: transformation of B cells by Epstein-Barr virus. Nat Rev Immunol 3: 801-812.
8. Thorley-Lawson DA, (2001) Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol 1: 75-82.
9. Hochberg D, Middeldorp JM, Catalina M, Sullivan JL, Luzuriaga K, et al. (2004) Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo. Proc Natl Acad Sci USA 101: 239-244.
10. Johannsen E, Miller CL, Grossman SR, Kieff E, (1996) EBNA-2 and EBNA-3C extensively and mutually exclusively associate with RBPJkappa in Epstein-Barr virus-transformed B lymphocytes. J Virol 70: 4179-4183.
11. Robertson ES, Lin J, Kieff E, (1996) The amino-terminal domains of Epstein-Barr virus nuclear proteins 3A, 3B, and 3C interact with RBPJ(kappa). J Virol 70: 3068-3074.
12. Zhao B, Sample CE, (2000) Epstein-barr virus nuclear antigen 3C activates the latent membrane protein 1 promoter in the presence of Epstein-Barr virus nuclear antigen 2 through sequences encompassing an spi-1/Spi-B binding site. J Virol 74: 5151-5160.
13. Knight JS, Lan K, Subramanian C, Robertson ES, (2003) Epstein-Barr virus nuclear antigen 3C recruits histone deacetylase activity and associates with the corepressors mSin3A and NCoR in human B-cell lines. J Virol 77: 4261-4272.
14. Radkov SA, Touitou R, Brehm A, Rowe M, West M, et al. (1999) Epstein-Barr virus nuclear antigen 3C interacts with histone deacetylase to repress transcription. J Virol 73: 5688-5697.
15. Subramanian C, Hasan S, Rowe M, Hottiger M, Orre R, et al. (2002) Epstein-Barr virus nuclear antigen 3C and prothymosin alpha interact with the p300 transcriptional coactivator at the CH1 and CH3/HAT domains and cooperate in regulation of transcription and histone acetylation. J Virol 76: 4699-4708.
16. Subramanian C, Cotter MA, 2nd, Robertson ES, (2001) Epstein-Barr virus nuclear protein EBNA-3C interacts with the human metastatic suppressor Nm23-H1: a molecular link to cancer metastasis. Nat Med 7: 350-355.
17. Knight JS, Sharma N, Robertson ES, (2005) Epstein-Barr virus latent antigen 3C can mediate the degradation of the retinoblastoma protein through an SCF cellular ubiquitin ligase. Proc Natl Acad Sci USA 102: 18562-18566.
18. Knight JS, Sharma N, Robertson ES, (2005) SCFSkp2 complex targeted by Epstein-Barr virus essential nuclear antigen. Mol Cell Biol 25: 1749-1763.
19. Knight JS, Sharma N, Kalman DE, Robertson ES, (2004) A cyclin-binding motif within the amino-terminal homology domain of EBNA3C binds cyclin A and modulates cyclin A-dependent kinase activity in Epstein-Barr virus-infected cells. J Virol 78: 12857-12867.
20. Bajaj BG, Murakami M, Cai Q, Verma SC, Lan K, et al. (2008) Epstein-Barr virus nuclear antigen 3C interacts with and enhances the stability of the c-Myc oncoprotein. J Virol 82: 4082-4090.
21. Saha A, Murakami M, Kumar P, Bajaj B, Sims K, et al. (2009) Epstein-Barr virus nuclear antigen 3C augments Mdm2-mediated p53 ubiquitination and degradation by deubiquitinating Mdm2. J Virol 83: 4652-4669.
22. Yi F, Saha A, Murakami M, Kumar P, Knight JS, et al. (2009) Epstein-Barr virus nuclear antigen 3C targets p53 and modulates its transcriptional and apoptotic activities. Virology 388: 236-247.
23. Charroux B, Pellizzoni L, Perkinson RA, Shevchenko A, Mann M, et al. (1999) Gemin3: A novel DEAD box protein that interacts with SMN, the spinal muscular atrophy gene product, and is a component of gems. J Cell Biol 147: 1181-1194.
24. Grundhoff AT, Kremmer E, Tureci O, Glieden A, Gindorf C, et al. (1999) Characterization of DP103, a novel DEAD box protein that binds to the Epstein-Barr virus nuclear proteins EBNA2 and EBNA3C. J Biol Chem 274: 19136-19144.
25. Krauer KG, Buck M, Belzer DK, Flanagan J, Chojnowski GM, et al. (2004) The Epstein-Barr virus nuclear antigen-6 protein co-localizes with EBNA-3 and survival of motor neurons protein. Virology 318: 280-294.
26. Voss MD, Hille A, Barth S, Spurk A, Hennrich F, et al. (2001) Functional cooperation of Epstein-Barr virus nuclear antigen 2 and the survival motor neuron protein in transactivation of the viral LMP1 promoter. J Virol 75: 11781-11790.
27. Cordin O, Banroques J, Tanner NK, Linder P, (2006) The DEAD-box protein family of RNA helicases. Gene 367: 17-37.
28. Rocak S, Linder P, (2004) DEAD-box proteins: the driving forces behind RNA metabolism. Nat Rev Mol Cell Biol 5: 232-241.
29. Ou Q, Mouillet JF, Yan X, Dorn C, Crawford PA, et al. (2001) The DEAD box protein DP103 is a regulator of steroidogenic factor-1. Mol Endocrinol 15: 69-79.
30. Yan X, Mouillet JF, Ou Q, Sadovsky Y, (2003) A novel domain within the DEAD-box protein DP103 is essential for transcriptional repression and helicase activity. Mol Cell Biol 23: 414-423.
31. Gillian AL, Svaren J, (2004) The Ddx20/DP103 dead box protein represses transcriptional activation by Egr2/Krox-20. J Biol Chem 279: 9056-9063.
32. Lee K, Pisarska MD, Ko JJ, Kang Y, Yoon S, et al. (2005) Transcriptional factor FOXL2 interacts with DP103 and induces apoptosis. Biochem Biophys Res Commun 336: 876-881.
33. Klappacher GW, Lunyak VV, Sykes DB, Sawka-Verhelle D, Sage J, et al. (2002) An induced Ets repressor complex regulates growth arrest during terminal macrophage differentiation. Cell 109: 169-180.
34. Saha A, Bamidele A, Murakami M, Robertson ES, (2010) EBNA3C attenuates the function of p53 through interaction with inhibitor of growth family proteins 4 and 5. J Virol 85: 2079-2088.
35. Cauchi RJ, Davies KE, Liu JL, (2008) A motor function for the DEAD-box RNA helicase, Gemin3, in Drosophila. PLoS Genet 4: e1000265.
36. Mouillet JF, Yan X, Ou Q, Jin L, Muglia LJ, et al. (2008) DEAD-box protein-103 (DP103, Ddx20) is essential for early embryonic development and modulates ovarian morphology and function. Endocrinology 149: 2168-2175.
37. Pellizzoni L, Charroux B, Rappsilber J, Mann M, Dreyfuss G, (2001) A functional interaction between the survival motor neuron complex and RNA polymerase II. J Cell Biol 152: 75-85.
38. Fischer U, Liu Q, Dreyfuss G, (1997) The SMN-SIP1 complex has an essential role in spliceosomal snRNP biogenesis. Cell 90: 1023-1029.
39. Rossoll W, Jablonka S, Andreassi C, Kroning AK, Karle K, et al. (2003) Smn, the spinal muscular atrophy-determining gene product, modulates axon growth and localization of beta-actin mRNA in growth cones of motoneurons. J Cell Biol 163: 801-812.
40. Young PJ, Day PM, Zhou J, Androphy EJ, Morris GE, et al. (2002) A direct interaction between the survival motor neuron protein and p53 and its relationship to spinal muscular atrophy. J Biol Chem 277: 2852-2859.
41. Heinzel T, Lavinsky RM, Mullen TM, Soderstrom M, Laherty CD, et al. (1997) A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature 387: 43-48.
42. Lee MB, Lebedeva LA, Suzawa M, Wadekar SA, Desclozeaux M, et al. (2005) The DEAD-box protein DP103 (Ddx20 or Gemin-3) represses orphan nuclear receptor activity via SUMO modification. Mol Cell Biol 25: 1879-1890.
43. Renouf B, Hollville E, Pujals A, Tetaud C, Garibal J, et al. (2009) Activation of p53 by MDM2 antagonists has differential apoptotic effects on Epstein-Barr virus (EBV)-positive and EBV-negative Burkitt's lymphoma cells. Leukemia 23: 1557-1563.
44. Pujals A, Renouf B, Robert A, Chelouah S, Hollville E, et al. (2011) Treatment with a BH3 mimetic overcomes the resistance of latency III EBV (+) cells to p53-mediated apoptosis. Cell Death Dis 2: e184.
45. Forte E, Luftig MA, (2009) MDM2-dependent inhibition of p53 is required for Epstein-Barr virus B-cell growth transformation and infected-cell survival. J Virol 83: 2491-2499.
46. O'Nions J, Turner A, Craig R, Allday MJ, (2006) Epstein-Barr virus selectively deregulates DNA damage responses in normal B cells but has no detectable effect on regulation of the tumor suppressor p53. J Virol 80: 12408-12413.
47. Cai QL, Knight JS, Verma SC, Zald P, Robertson ES, (2006) EC5S ubiquitin complex is recruited by KSHV latent antigen LANA for degradation of the VHL and p53 tumor suppressors. PLoS Pathog 2: e116.
48. Aiello L, Guilfoyle R, Huebner K, Weinmann R, (1979) Adenovirus 5 DNA sequences present and RNA sequences transcribed in transformed human embryo kidney cells (HEK-Ad-5 or 293). Virology 94: 460-469.
49. Ponten J, Saksela E, (1967) Two established in vitro cell lines from human mesenchymal tumours. Int J Cancer 2: 434-447.
50. Clements GB, Klein G, Povey S, (1975) Production by EBV infection of an EBNA-positive subline from an EBNA-negative human lymphoma cell line without detectable EBV DNA. Int J Cancer 16: 125-133.
51. Robertson ES, Grossman S, Johannsen E, Miller C, Lin J, et al. (1995) Epstein-Barr virus nuclear protein 3C modulates transcription through interaction with the sequence-specific DNA-binding protein J kappa. J Virol 69: 3108-3116.
52. Knight JS, Robertson ES, (2004) Epstein-Barr virus nuclear antigen 3C regulates cyclin A/p27 complexes and enhances cyclin A-dependent kinase activity. J Virol 78: 1981-1991.
53. Laemmli UK, (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685.
54. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, et al. (1998) A third-generation lentivirus vector with a conditional packaging system. J Virol 72: 8463-8471.
55. Wei F, Zaprazna K, Wang J, Atchison ML, (2009) PU.1 can recruit BCL6 to DNA to repress gene expression in germinal center B cells. Mol Cell Biol 29: 4612-4622.
56. Bai Y, Srinivasan L, Perkins L, Atchison ML, (2005) Protein acetylation regulates both PU.1 transactivation and Ig kappa 3' enhancer activity. J Immunol 175: 5160-5169.